MDLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Medline Inc (MDLN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential, as evidenced by its revenue growth, positive analyst sentiment, and recent IPO success. While there are some short-term challenges, such as declining net income and EPS, the long-term outlook and positive catalysts outweigh these concerns.
The technical indicators are bullish. The MACD is above 0 and positively contracting, indicating upward momentum. The RSI is neutral at 60.529, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm a bullish trend. The stock is trading near its pivot level of 47.386, with resistance levels at 50.177 and 51.901, suggesting room for upward movement.
Strong revenue growth of 14.78% YoY in Q4
Successful IPO raising $6.26 billion, reflecting strong investor confidence.
Positive analyst sentiment with multiple price target upgrades and buy ratings.
Broad-based strength across segments and geographies, as highlighted in Q4 results.
Declining net income (-37.02% YoY) and EPS (-36.36% YoY) in Q4
Gross margin dropped by 9.56% YoY, indicating cost pressures.
No significant insider or hedge fund trading activity, suggesting neutral sentiment from key stakeholders.
In Q4 2025, Medline reported revenue of $7.787 billion, up 14.78% YoY, but net income dropped to $182 million (-37.02% YoY), and EPS fell to 0.14 (-36.36% YoY). Gross margin also declined to 22.32% (-9.56% YoY). Despite these challenges, the company demonstrated strong sales growth and forward revenue visibility.
Analysts are highly positive on Medline, with multiple firms raising price targets to $55-$60 and maintaining buy or outperform ratings. Analysts cite strong Q4 results, broad-based growth, and a compelling long-term growth algorithm as reasons for their optimism.
